A MULTIFACETED DIGITAL HEALTH PLATFORM TO ADVANCE ALZHEIMER'S DISEASE PATIENT MONITORING, SAFETY, CARE, AND RESEARCH.

一个多层面的数字健康平台，可推进阿尔茨海默病患者的监测、安全、护理和研究。

• 批准号: 10325493
• 负责人: Jon Andrew Corkey
• 金额: $ 49.58万
• 依托单位: AMISSA, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-01 至 2023-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10325493
• 关键词: Affect; Aging; Alzheimer' s Disease; Alzheimer' s disease patient; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; American; Americas; Anxiety; Appointment; Architecture; Artificial Intelligence; Authorization documentation; Behavior; Behavioral; Biological Markers; Biometry; Caregiver Burden; Caregivers; Caring; Cellular Phone; Clinical Trials; Collection; Computer software; Dangerousness; Data; Data Collection; Databases; Decentralization; Dementia; Dementia caregivers; Detection; Devices; Disease; Disease Progression; Early Diagnosis; Elderly; Emergency Situation; Environment; Exhibits; Family; Feedback; Feeling; Fees; Frequencies; Future; Goals; Health; Health Insurance Portability and Accountability Act; Health behavior; Heart Rate; Home; Hour; Individual; Intervention; Intervention Studies; Interview; Knowledge; Life; Location; Longevity; Longitudinal trends; Measures; Medical Research; Mind; Minority Groups; Modeling; Monitor; Notification; Onset of illness; Outcome; Parents; Patient Care; Patient Monitoring; Patient Recruitments; Patient Self-Report; Patient Transfer; Patients; Pattern; Performance; Personal Computers; Personal Satisfaction; Persons; Phase; Phenotype; Physical Exercise; Physicians; Population; Population Heterogeneity; Preventive treatment; Process; Public Health; Quality of life; Research; Research Personnel; Research Support; Resources; Rural Population; S Phase; Safety; Sampling; Scientist; Secure; Shame; Small Business Innovation Research Grant; Stigmatization; Stress; Symptoms; Techniques; Technology; Testing; Time; Travel; United States National Institutes of Health; Universities; Visual; base; caregiving; clinically relevant; cloud based; community based evaluation; cost; dashboard; data exchange; design; digital; digital health; experience; falls; handheld mobile device; humiliation; improved; insight; lifestyle intervention; loved ones; meetings; mobile application; modifiable behavior; multimodal data; novel; patient safety; peace; prevent; prototype; racial minority; recruit; remote monitoring; remote patient monitoring; rural underserved; sedentary lifestyle; sensor; sleep behavior; smart watch; social; social stigma; socialization behavior; tool; volunteer

Project Summary Alzheimer’s Disease (AD) and AD-Related Dementias (ADRD) are projected to affect 50 million Americans by 2050. In 2019, more than 16 million Americans struggled while providing unpaid care for people with AD/ADRD and they need stigma-free solutions to help remotely monitor challenging AD/ADRD behaviors like falling and wandering. Separate but related, many AD/ADRD clinical trials are siloed and require patient volunteers and their caregivers to travel to in-person appointments. This is burdensome for families, increases the cost to conduct studies, and data collected is often non-representative of daily life. Amissa Inc. has developed a stigma- free, prototype solution to significantly advance AD/ADRD patient monitoring, safety, and caregiving while simultaneously aggregating high-frequency digital biomarkers to advance medical research. Several competitors have developed hardware devices for tracking elderly individuals who wander and/or fall however, AD/ADRD patients express feelings of stress, anxiety, humiliation, burden, and stigma associated with dementia when wearing these “special” devices. AD/ADRD caregivers seek “socially-acceptable” devices that improve health and location monitoring, provide peace of mind, reduce worry, improve patient safety and quality of life without loved ones feeling shame or embarrassment. Amissa’s prototype software application, created for widely available, consumer-grade smartwatches, enables families to remotely monitor when loved ones fall inside or outside the home and help prevent dangerous wandering episodes. Our initial software application also sends emergency push notifications to key stakeholders when loved ones exhibit uncommon behaviors (e.g. sudden change in variable heart rate). This Phase I SBIR proposal is designed to develop a platform which passively and unobtrusively collects time-based behavioral and biometric data from AD/ADRD patient smartwatches in real-life settings to improve caregiving while also establishing a high-frequency cloud database where one does not currently exist for AD/ADRD research. Aim 1 will develop a caregiver-designed AD/ADRD patient monitoring application for off-the-shelf consumer smartwatches and conduct user-experience and user-interface testing to facilitate feedback for iterative product design improvement. Utilizing opt-in user data from Amissa’s caregiver monitoring application, Aim 2 will establish a novel high-frequency behavioral and biometric cloud database to advance AD/ADRD digital biomarker research capabilities to predict patient falls an wandering. Amissa’s project intends to enable faster collection of multimodal data via broader demographic populations to advance AD/ADRD medical research. This Phase I SBIR has the potential for high impact by providing a single, low-cost, digital technology solution to improve AD/ADRD patient care and safety while reducing stress for caregivers and families. Furthermore, this research will improve capabilities and reduce costs of conducting decentralized clinical trials in real-life environments. At scale, our goal is to advance the forecasting of symptom trajectories and enable physicians to suggest personalized preventative treatments to delay onset or prevent AD/ADRD.

项目摘要 阿尔茨海默病（AD）和AD相关痴呆症（ADRD）预计将影响5000万美国人， 2050. 2019年，超过1600万美国人在为AD/ADRD患者提供无偿护理时挣扎 他们需要无污名的解决方案来帮助远程监测具有挑战性的AD/ADRD行为，如跌倒， 游荡独立但相关的许多AD/ADRD临床试验是孤立的，需要患者志愿者和 他们的护理人员前往亲自预约。这对家庭来说是沉重的负担， 开展研究，收集的数据往往不能代表日常生活。阿米萨公司已经形成了一种耻辱感 免费的原型解决方案，可显著推进AD/ADRD患者监测、安全性和诊断， 同时聚合高频数字生物标志物以推进医学研究。几个竞争对手 已经开发了硬件设备，用于跟踪徘徊和/或跌倒的老年人，AD/ADRD 患者表达与痴呆相关的压力、焦虑、羞辱、负担和耻辱感， 戴着这些“特殊”的装置AD/ADRD护理人员寻求“社会可接受”的设备，以改善健康 和位置监控，让患者安心，减少担忧，提高患者安全性和生活质量， 所爱的人感到羞耻或尴尬。Amissa的原型软件应用程序， 可用的消费级智能手表，使家庭能够远程监控亲人何时落入家中， 帮助防止危险的流浪事件。我们的初始软件应用程序还发送 当所爱的人表现出不寻常的行为（例如，突然 可变心率的变化）。第一阶段SBIR提案旨在开发一个平台， 并从AD/ADRD患者智能手表中不显眼地收集基于时间的行为和生物特征数据， 现实生活中的设置，以改善浏览，同时也建立了一个高频云数据库， 目前还不存在AD/ADRD研究。Aim 1将开发一个由美国设计的AD/ADRD患者监测系统 应用现成的消费者智能手表，并进行用户体验和用户界面测试， 便于反馈，以便迭代产品设计改进。利用Amissa护理人员的选择加入用户数据 Aim 2将建立一个新的高频行为和生物特征云数据库， 推进AD/ADRD数字生物标志物研究能力，以预测患者福尔斯和徘徊。Amissa的项目 旨在通过更广泛的人口统计学人群更快地收集多模态数据，以推进AD/ADRD 医学研究第一阶段SBIR通过提供单一、低成本、数字化的 改善AD/ADRD患者护理和安全性的技术解决方案，同时减轻护理人员的压力， 家庭此外，这项研究将提高能力，降低进行分散管理的成本。 在现实环境中进行临床试验。在规模上，我们的目标是推进症状轨迹的预测 并使医生能够建议个性化的预防性治疗，以延迟发病或预防AD/ADRD。